Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Kaltura Inc (KLTR) Price & Performance

Heron Therapeutics IncTrade
Kaltura IncTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Kaltura Inc — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Kaltura Inc trades at $1.37 (market cap $208.27M). The key difference: Kaltura Inc is far larger — about 2.3× Heron Therapeutics Inc's market cap, and Kaltura Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXKLTR
Market Cap
$91.46M$208.27M
Sector
HealthTechnology
52-Week High
$1.96$1.97
52-Week Low
$0.39$1.08
Enterprise Value
$189.36M$190.99M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

Kaltura Inc

Kaltura (KLTR) trades at $1.385, down 0.36% with a bullish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and revenue stabilizing around $180M. Recent industry recognition includes being named a Leader in virtual event platforms by Forrester and Aragon Research in June 2026. Operating cash flow turned positive in Q1 2026 for the first time in company history, though net margins remain negative at -8.25%.

While technical indicators suggest near-term strength, fundamental challenges persist with negative ROE of -107.84% and high P/B ratio of 44.85. Analyst consensus leans bullish with 44% buy ratings, but profitability concerns and competitive pressures in the digital experience platform space warrant caution. The upcoming Q2 2026 earnings on August 5 will be critical for validating the company's turnaround trajectory.

Returns comparison

Trailing returns across standard periods

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Kaltura Inc

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)

Read more on KLTR